The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
13 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $18,597,269 in first-year total cost, median $441,269.
Most frequent study sections
- Special Emphasis Panel[ZEY1 VSN (01)]12
- Special Emphasis Panel[ZEY1 VSN (06)]1
Most frequent institutions
- JAEB CENTER FOR HEALTH RESEARCH, INC.2
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
- EMORY UNIVERSITY1
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI1
- JOHNS HOPKINS UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | DRCR Network2UG1EY014231-18 | GLASSMAN, ADAM RMARTIN, DANIEL FSUN, JENNIFER KATHERINE | JAEB CENTER FOR HEALTH RESEARCH, INC., FL | $8,500,000 | ZEY1 |
| 2019 | Pediatric Eye Disease Investigator Group Network2UG1EY011751-23 | COTTER, SUSAN ANNEHOLMES, JONATHAN MKRAKER, RAYMOND | JAEB CENTER FOR HEALTH RESEARCH, INC., FL | $4,953,324 | ZEY1 |
| 2019 | The SCORE2 Long-Term Follow-Up (SCORE2 LTF)2UG1EY023533-06 | SCOTT, INGRID U | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $1,082,515 | ZEY1 |
| 2019 | Examination of Myopia Progression and Consequences and Mechanism of Soft Multifocal Contact Lens Myopia Control2UG1EY023208-06 | WALLINE, JEFFREY JAY | OHIO STATE UNIVERSITY, OH | $120,866 | ZEY1 |
| 2018 | Village-Integrated Eye Worker trial II (VIEW II)1UG1EY028097-01A1 | KEENAN, JEREMY DAVID | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $720,389 | ZEY1 |
| 2018 | The Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion1UG1EY026876-01A1 | PARK, SUSANNA S | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $464,984 | ZEY1 |
| 2018 | ADalimumab Versus conventional ImmunoSupprEssion for uveitis (ADVISE) Trial1UG1EY028096-01A1 | JABS, DOUGLAS A | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $171,980 | ZEY1 |
| 2017 | Comparative Effectiveness Research & Cochrane Eyes and Vision (CEV)2UG1EY020522-08 | DICKERSIN, KAY | JOHNS HOPKINS UNIVERSITY, MD | $999,848 | ZEY1 |
| 2017 | Kebele Elimination of Trachoma for Ocular Health1UG1EY028088-01 | LIETMAN, THOMAS MOLDENBURG, CATHERINE ELIZABETH | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $441,269 | ZEY1 |
| 2017 | Safety and Feasibility of Cultivated Autologous Limbal Epithelial Cell (CALEC) Transplantation in the Treatment of Limbal Stem Cell Deficiency1UG1EY026508-01A1 | JURKUNAS, ULA V. | MASSACHUSETTS EYE AND EAR INFIRMARY, MA | $381,858 | ZEY1 |
| 2016 | Evaluating the Role of Incision Height in Improving Trichiasis Surgery Outcomes1UG1EY025992-01 | GOWER, EMILY W | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $92,581 | ZEY1 |
| 2015 | Ocular Hypertension Treatment Study 20-Year Follow-up: Chairman's Grant1UG1EY025180-01 | KASS, MICHAEL A | WASHINGTON UNIVERSITY, MO | $421,995 | ZEY1 |
| 2015 | Infant Aphakia Treatment Study-Chairman's Grant2UG1EY013272-13 | LAMBERT, SCOTT R | EMORY UNIVERSITY, GA | $245,660 | ZEY1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.